GE HealthCare’s earnings coverage emphasises an improving outlook. A report describes an earnings beat and raised guidance, while another report discusses investment in PET supply and an imaging initiative. The company’s SEC-derived figures through FY2026 Q3 support optimism about cash generation, with an important qualification: trailing free cash flow grew 34.9% while net income fell 2.8%.
Those reports concern the same fiscal quarter covered by the figures here. The distinction is the measurement period. A favourable quarterly earnings report can coexist with weaker profit across the trailing year. GE HealthCare’s cash improvement deserves attention precisely because it developed alongside that weaker earnings record.
GE HealthCare free cash flow improved despite higher investment
For the trailing year through FY2026 Q3, GE HealthCare generated $1.9 billion in free cash flow. Operating cash flow reached $2.4 billion, up 30.5%, while capital expenditure increased 16.9% to $526.0 million.
That combination rules out a simple explanation based on cutting purchases of property, plant and equipment. Cash generation improved while that spending increased. It does not establish why operating cash flow rose, but it places the improvement within the cash coming from operations rather than a reduction in this category of investment.
| Measure | Trailing year through FY2026 Q3 |
|---|---|
| Free cash flow growth | +34.9% |
| Net income growth | −2.8% |
| Free cash flow margin | 8.7% |
| Free cash flow margin change | +1.8 percentage points |
| Revenue growth | +6.9% |
Revenue also helped. Trailing sales reached $21.6 billion, growing 6.9%. Yet the cash improvement extended beyond a larger sales base: the free cash flow margin widened, meaning more cash remained after capital expenditure for each dollar of revenue.
The distinction matters to the reported expansion plans. Stronger internally generated cash gives GE HealthCare greater capacity to fund investment. These figures do not identify the cost of the reported PET initiative or establish how it will be financed. They therefore support an assessment of funding capacity, rather than a verdict on that transaction.
Cash improved faster than operating profitability
The trailing operating margin through FY2026 Q3 was 13.3%, down 0.2 percentage points from the year-earlier period. Sales growth had not translated into a wider operating margin.
This is the strongest reason to resist treating the cash improvement as proof of a broad improvement in profitability. Operating profit measures the earnings generated by the business before financing and tax effects. Cash flow also reflects when customers pay and when the company settles its obligations. Their different movements require explanation before either becomes a reliable guide to future performance.
The reasonable alternative reading is that GE HealthCare is recovering cash after an unusually weak comparison period. Its trailing free cash flow margin of 8.7% remained below the historical maximum of 9.9% in the available observations. The improvement could represent a return towards previously achieved cash generation, rather than a new level of performance.
The aggregate figures cannot separate working-capital timing from lasting operational changes. Nor do they explain the decline in net income. A claim that the earnings coverage confirms a durable cash recovery would go further than this evidence permits.
GE HealthCare’s model value depends on cash-margin persistence
If the past year’s improvement persists, the model assigns it a +40.7% change in value, holding other assumptions constant.
That conditional result connects the central finding to intrinsic value: a sustained increase in cash generated from revenue changes the cash available in future periods. A fall of one percentage point in free cash flow margin produces a model value change of −15.9%.
Growth remains consequential. Against the model’s base growth assumption of 6.9%, growth five percentage points lower produces a −34.6% value change; growth five percentage points higher produces +45.1%. A discount rate one percentage point higher produces −20.6%.
The margin-persistence result and the growth sensitivities are both substantial. The earnings coverage offers reasons to examine expansion, but the filings make the durability of cash conversion equally relevant to the model’s valuation assessment. These are model values under stated assumptions, not a comparison with the share price.